The Canada Carrier Screening Market was valued at $124.5 Million in 2023 and projected to reach to $284.4 Million by 2028, representing a compound annual growth rate of 18.0%. Canada's carrier screening market is positioned for sustained growth through 2028, driven by increasing integration of genetic testing into standard prenatal care protocols and expanding access across provincial healthcare systems.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada's carrier screening market reached $124.5 million in 2023 and is projected to grow to $284.4 million by 2028, representing an 18% CAGR—demonstrating strong market expansion driven by technological adoption and healthcare investment.
Canada's publicly funded healthcare system and advanced medical infrastructure provide a stable foundation for carrier screening adoption, with provincial health authorities increasingly integrating genetic testing into prenatal and reproductive health programs.
Increasing awareness among Canadian prospective parents about hereditary disease risks and the availability of non-invasive prenatal testing (NIPT) options is driving demand for comprehensive carrier screening services across major metropolitan areas.
Canadian regulatory bodies and clinical guidelines are progressively supporting carrier screening implementation, with major hospitals and fertility clinics expanding genetic testing capabilities to meet growing patient demand and clinical best practices.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | PULMONARY CONDITIONS (Medical Condition) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 19.7% from 2023 to 2028 |
| Largest Segment | SERVICES (Product & Service) |
| Market Size Base Year (Billions) | ~USD 2.2 (2023) |
| Revenue Forecast (Billions) | ~USD 5.4 (2028) |
| Segments Covered | Product & Service, Type, Medical Condition, Technology, End User, Product & 2021-2028 |
6 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 22.7 | 26.4 | 31 | 36.3 | 42.5 | 49.8 | 58.3 | 69 | 17.4 |
| FERTILITY CLINICS | 9.2 | 10.6 | 12.2 | 14.1 | 16.2 | 18.7 | 21.6 | 25.2 | 15.6 |
| HOSPITALS AND MEDICAL CENTERS | 53.8 | 63.4 | 75.3 | 89.4 | 106 | 125.8 | 149.3 | 178.7 | 18.9 |
| OTHER END USERS | 4.7 | 5.3 | 6 | 6.8 | 7.8 | 8.9 | 10.1 | 11.6 | 14 |
| TOTAL | 90.4 | 105.7 | 124.5 | 146.6 | 172.5 | 203.2 | 239.3 | 284.4 | 18 |
Canada's carrier screening market was valued at $124.5 million in 2023 and is expected to reach $284.4 million by 2028, growing at an 18.0% CAGR.
Growth in Canada is driven by increased adoption of genetic testing, rising awareness among prospective parents, supportive provincial reimbursement policies, declining test costs, and integration into prenatal care protocols.
Canada's carrier screening market focuses on conditions including cystic fibrosis, sickle cell disease, Tay-Sachs disease, and other hereditary disorders, with ethnicity-specific panels tailored to Canada's diverse population.
Canada's healthcare system supports carrier screening through enhanced reimbursement policies, integration into prenatal care programs, investment in laboratory infrastructure, and collaboration between provincial health authorities and private diagnostic providers.
Canada's carrier screening market is forecast to reach $284.4 million by 2028, representing more than a doubling of the 2023 market value of $124.5 million.
The study involved four major activities in estimating the current size of the Carrier Screening Market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Doctors, Surgeons, Gynecologist, genetic consultant) and supply sides (Carrier Screening product/service providers and distributors).
The following is a breakdown of the primary respondents:

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2. Tiers of companies are defined based on their total revenue. As of 2021: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Carrier Screening Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Carrier Screening Market industry.
Carrier screening is a type of genetic testing that is used to determine if a person is a carrier for a specific autosomal recessive disease. Similarly, when it is done before or during pregnancy, it allows to find out the chances of having a child with a genetic disorder. Carrier screening involves testing a sample of blood, saliva, or tissue from the inside of the cheek.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Carrier Screening Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report